Skip to content

Seek Feedback

Opportunity

The experience of patients participating in clinical trials may not consistently meet expectations. Poor participant experience is a negative influencer of recruitment, retention, and reputation. Therefore, it is important to provide clinical trial participants with the opportunity to provide feedback on various aspects of the study (including the study information, assessments, visit type / schedule, devices, the site and impact on their time) to improve participant experience on current and future studies.

Considerations to Help Action the Opportunity

  • Define the factors that impact patient experience during a trial. Factors may include quality of care (e.g., treatment, inclusion / exclusion criteria), ease and convenience (e.g., site / location, travel, reimbursement), connection and human touch (e.g., communication, information, site staff)
  • Understand which tools can be utilized to collect participant feedback and measure these patient experience factors. This could include both qualitative methods, like in trial or exit interview, or quantitative participant feedback questionnaires (e.g., optional surveys) administered at different timepoints on the study. Understand whether these tools cover all countries of interest (where the sponsor is allowed to operate)
  • Utilize standardized participant feedback tactics to help elicit actionable participant feedback to potentially reduce patient burden
  • Consult clinical sites early for their input into standardized participant feedback tactics to better enable rapid identification of actionable participant insights and facilitated implementation of mitigation actions at site level
  • Standardize the collection of participant feedback within the organization, to enable cross-study aggregation of data for identification of significant insights not possible at an individual study level (e.g., identify specific patient populations with low patient experience)
  • Clearly define how to analyze, visualize and interpret patient experience data
  • Provide study teams access to the data in real-time to better enable actionable insights at study and site level
  • Provide sites with aggregated (anonymized) learnings to better enable them to take actions to potentially improve patient experience at their site
  • Provide patients with aggregated (anonymized) feedback and actions taken to demonstrate to them the value of providing feedback and help motivate further engagement with clinical trials
  • Embed the process to collect, analyze and interpret patient experience feedback into existing processes to help limit burden on study team

Value and Potential Benefits

  • Provides study teams with actionable feedback so they can take steps to reduce burden on current and future studies to potentially improve the patient’s experience in clinical studies
  • Increases patient adherence and compliance to clinical study procedures, which consequently improves the data quality
  • Increases trust and engagement through better communication and participation in feedback processes
  • Potentially increases recruitment into trials and reduces study participant dropout rates

Related Blog Posts

A Toolkit for ICH-E6(R3)

Released at the start of 2025, the ICH-E6(R3) guideline is an updated international standard for how clinical trials should be designed, conducted, recorded, and reported. At its core, the guideline ensures that people who participate in clinical trials are kept safe and that the data collected is reliable and meaningful. This guideline is not a…

Expanding clinical trial access through technology, support

Clinical trials are a key tool for producing the safety and efficacy data that guide new therapies to market. Progress in clinical research relies on those who volunteer to participate, and yet, access to trials is not the same for everyone in the United States. Read the full article featuring Allison Cuff Shimooka from TechTarget…

Good Clinical Practice has Changed: Are You Ready for ICH-E6(R3)?

ICH-E6(R3) represents a shift in mindset when it comes to clinical trials. Rather than trying to control every part of a trial equally, the guideline wants researchers to focus most on factors that are critical to participant safety and the reliability of trial results. It introduces the idea of “proportionality,” meaning more control is applied…